CClinicalTrials.gg
CompletedNCT04913766RECOUP-NYUpdated May 28, 2026

REstoring Mental Health Through COmmUnity-based Psychological Services in New York City

An interventional study of Problem Management Plus and Services as Usual in Depression, Anxiety and Psychological Distress, sponsored by George Washington University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by George Washington University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1,206
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal is to improve mental health. The study will evaluate the impact of community-based mental health services. Successful completion of this study will contribute to the National Institute of Mental Health Strategic Plan employing implementation science to maximize the public health impact of research for effectiveness and reach of mental health services in the United States.

Read the detailed description

There is a need for delivery of psychological interventions by non-specialists when specialists are unable to meet the service demand. In the United States, training staff at community-based organizations to deliver psychological support has been highlighted as a way to increase availability of mental health services and increase access to mental health care, particularly for underserved populations. This study employs a mental health task-sharing model by partnering with community based organizations in New York City to train community based organizations staff without professional mental health training to deliver mental health services. This study examine the impact of community based organizations staff delivering mental health services to reduce mental health problems. This study is a cluster randomized control trial in New York City comparing Services as Usual arm and delivery of mental health services with Problem Management Plus (Intervention arm) among participating community based organizations. The target condition will be general psychological distress. This study will evaluate mental health outcomes populations served by community based organizations integrating Problem Management Plus into their other activities compared to community based organizations delivering services as usual. This study will evaluate implementation science outcomes to inform policy recommendations for of community-based delivery of psychological interventions. Successful completion of these aims will contribute to the 2020 National Institute of Mental Health Strategic Plan. Specifically, a) employing implementation science to maximize the public health impact of research for improving effectiveness and reach of mental health services, b) strengthening research-practice partnerships to expedite adoption, sustained implementation, and continuous improvement of evidence-based mental health services, and c) developing innovative service delivery models to dramatically improve outcomes of mental health services.

02

Conditions studied

  • Depression
  • Anxiety
  • Psychological Distress
  • PTSD
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 1,206 is above the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

George Washington University is the lead sponsor of 187 studies on the registry; 34 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Persons with Patient Health Questionnaire 4 scores equal to or above 3
  • Functional impairment associated with psychological distress

Exclusion criteria

Exclusion Criteria:

  • Acute suicide risk
  • Patient Health Questionnaire 4 score below 3
  • No functional impairment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,206 participants (actual)

Study arms

  • Active comparator
    Services as usual

    Persons screening positive for depression will be referred from community-based organizations. The referrals will be made to mental health specialists who will provide care based on their standard of care.

    Behavioral: Services as Usual

  • Experimental
    Problem Management Plus

    Persons screening positive for depression will be offered Problem Management Plus delivered by community based organization staff.

    Behavioral: Problem Management Plus

Interventions

  • BehavioralProblem Management Plus

    Five session psychological intervention focusing on problem management skills.

  • BehavioralServices as Usual

    Mental health services provided by a mental health specialists according to their standard practices of care

06

What researchers measure

Primary outcomes

  1. Psychological Outcome Profiles Questionnaire; Unabbreviated scale title "Psychological Outcome Profiles questionnaire"

    4-item self-report questionnaire that is a personalized measure of psychological distress.

    Time frame: 20 weeks after baseline assessment

Secondary outcomes

  1. Patient Health Questionnaire 9; Unabbreviated scale title "Patient Health Questionnaire 9"

    9-item self-report scale to assess symptoms of depression, minimum value=0, maximum value=27, higher scores mean greater depression symptoms

    Time frame: 20 weeks after baseline assessment

  2. Generalized Anxiety Disorder 7; Unabbreviated scale title "Generalized Anxiety Disorder 7"

    7-item self-report scale to assess symptoms of depression, minimum value=0, maximum value=21, greater scores mean more anxiety symptoms

    Time frame: 20 weeks after baseline assessment

  3. Posttraumatic Stress Disorder Checklist 5; Unabbreviated scale title "Posttraumatic Stress Disorder Checklist 5"

    8-item self-report scale for symptoms of posttraumatic stress disorder, minimum value=0, maximum value=24, greater scores mean more posttraumatic stress symptoms

    Time frame: 20 weeks after baseline assessment

Other outcomes

  1. Reducing Tension Checklist, Unabbreviated title "Reducing Tension Checklist"

    10 items self-report scale for psychosocial skill use, minimum score=0, maximum score=30, greater scores mean more skill use

    Time frame: 10 weeks after baseline assessment

  2. Intolerance of Uncertainty Scale-Short Form; Unabbreviated title "Intolerance of Uncertainty Scale-Short Form"

    12-item self-report of responses to uncertainty, ambiguous situations, and the future

    Time frame: 10 weeks after baseline assessment

07

Study locations

1 site
  • New School
    New York, New York 10036, United States
08

References and documents

Individual participant data

Plan to share: Yes — Individual Participant Data will be shared through National Institute of Mental Health Data Archive

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04913766
Lead sponsor
George Washington University
Collaborators
The New School, Duke University, Human Sciences Research Council
Responsible party
Brandon A Kohrt, MD, PhD (Professor, George Washington University) — Principal investigator
First posted
Jun 4, 2021
Start date
Oct 25, 2022
Primary completion
Feb 9, 2026
Completion
Feb 9, 2026
Last update
May 28, 2026

Study contacts

Brandon Kohrt, MD, PhD
principal investigator · George Washington University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion